Psoriasis

Brodalumab met all primary endpoints against its first-in-class rival, ustekinumab, and against placebo in two phase III trials of more than 3,700 patients with moderate to severe plaque psoriasis, investigators reported in the New England Journal of Medicine.

The results of the two studies, AMAGINE-2 and AMAGINE-3, were published on Sept. 30 (N Eng J Med. 2015;373:1318-28).

“The data for brodalumab are the best data we’ve seen. It literally is twice as effective at achieving PASI [Psoriasis Area Severity Index] 100 as ustekinumab, which is a spectacular drug,” lead investigator Dr. Mark Lebwohl said in an interview. “More than two-thirds of patients achieved PASI 90. We’ve never seen data like this before,” said Dr. Lebwohl, professor and chairman of the department of dermatology at Icahn School of Medicine at Mount Sinai, New York.

Dermatologists and patients have closely followed brodalumab, an investigational interleukin-17 receptor A inhibitor, which, in March 2015, was reported to have doubled the PASI 100 response rate of ustekinumab in the AMAGINE-2 trial. But 2 months later, Amgen pulled funding and ended its partnership with AstraZeneca on the biologic in the wake of suicides of two patients who had recently completed brodalumab treatment. At the time, Amgen stated that it was concerned that brodalumab would receive restrictive labeling related to suicidal ideation and behavior. An Amgen spokeswoman on Sept. 29 declined to elaborate.

On Sept. 1, however, Valeant Pharmaceuticals announced that it was partnering with AstraZeneca to continue with plans to develop and commercialize brodalumab and that regulatory submissions in the United States and the European Union were planned for the 4th quarter of 2015.

In the interview, Dr. Lebwohl said he did not know of a mechanism by which blocking the IL-17 receptor might increase the risk of depression or suicide. “But psoriasis is certainly associated with depression,” he added. “Two out of more than 3,700 patients committed suicide over more than a year, and that could certainly be attributable to the depression associated with the underlying skin disease.”

AMAGINE-2 and AMAGINE-3 were replicate phase III, double-blind, randomized, controlled trials of 3,712 patients with moderate to severe plaque psoriasis. In the two studies, week 12 PASI 75 rates were about 85% with 210 mg of brodalumab, about 68% for 140 mg of brodalumab, and 6%-8% for placebo (P less than .001). Moreover, week 12 PASI 100 response rates with 210 mg of brodalumab were 37% and 44%, compared with 19% and 22% for ustekinumab (P less than .001), the investigators reported.

Median time to PASI 75 on 210 mg of brodalumab was 4 weeks – about twice as fast as for ustekinumab. Rates of static Physician’s Global Assessment (sPGA) scores of 0 or 1 (clear or almost clear skin) also were significantly higher for brodalumab, compared with placebo (P less than .001).

Mild to moderate candidiasis was more common during induction of brodalumab, compared with ustekinumab or placebo, underscoring the role of interleukin-17A in microbial surveillance, Dr. Lebwohl and his associates pointed out. They estimated that 1-1.3 serious infections occurred for every 100 patient-years of exposure to brodalumab, through 52 weeks.

The investigators reported but did not comment on the suicides, stating only that the study populations were large enough to assess common adverse events but “may have been inadequate for the detection of rare adverse events, which would require longer follow-up of large numbers of patients to provide a full understanding of the safety profile of brodalumab.”

Ustekinumab is marketed as Stelara.

Amgen funded the AMAGINE-2 and AMAGINE-3 studies. Dr. Lebwohl reported having received grant support from Amgen, AbbVie, Janssen Biotech, UCB Pharma, Pfizer, Celgene, Eli Lilly, and Novartis outside the submitted work. Twenty-four coauthors reported grant support or personal fees from Amgen, Abbvie, Merck, Janssen, and several other pharmaceutical companies. The other investigators declared no competing interests.

Brodalumab met all primary endpoints against its first-in-class rival, ustekinumab, and against placebo in two phase III trials of more than 3,700 patients with moderate to severe plaque psoriasis, investigators reported in the New England Journal of Medicine.

The results of the two studies, AMAGINE-2 and AMAGINE-3, were published on Sept. 30 (N Eng J Med. 2015;373:1318-28).

“The data for brodalumab are the best data we’ve seen. It literally is twice as effective at achieving PASI [Psoriasis Area Severity Index] 100 as ustekinumab, which is a spectacular drug,” lead investigator Dr. Mark Lebwohl said in an interview. “More than two-thirds of patients achieved PASI 90. We’ve never seen data like this before,” said Dr. Lebwohl, professor and chairman of the department of dermatology at Icahn School of Medicine at Mount Sinai, New York.

Dermatologists and patients have closely followed brodalumab, an investigational interleukin-17 receptor A inhibitor, which, in March 2015, was reported to have doubled the PASI 100 response rate of ustekinumab in the AMAGINE-2 trial. But 2 months later, Amgen pulled funding and ended its partnership with AstraZeneca on the biologic in the wake of suicides of two patients who had recently completed brodalumab treatment. At the time, Amgen stated that it was concerned that brodalumab would receive restrictive labeling related to suicidal ideation and behavior. An Amgen spokeswoman on Sept. 29 declined to elaborate.

On Sept. 1, however, Valeant Pharmaceuticals announced that it was partnering with AstraZeneca to continue with plans to develop and commercialize brodalumab and that regulatory submissions in the United States and the European Union were planned for the 4th quarter of 2015.

In the interview, Dr. Lebwohl said he did not know of a mechanism by which blocking the IL-17 receptor might increase the risk of depression or suicide. “But psoriasis is certainly associated with depression,” he added. “Two out of more than 3,700 patients committed suicide over more than a year, and that could certainly be attributable to the depression associated with the underlying skin disease.”

AMAGINE-2 and AMAGINE-3 were replicate phase III, double-blind, randomized, controlled trials of 3,712 patients with moderate to severe plaque psoriasis. In the two studies, week 12 PASI 75 rates were about 85% with 210 mg of brodalumab, about 68% for 140 mg of brodalumab, and 6%-8% for placebo (P less than .001). Moreover, week 12 PASI 100 response rates with 210 mg of brodalumab were 37% and 44%, compared with 19% and 22% for ustekinumab (P less than .001), the investigators reported.

Median time to PASI 75 on 210 mg of brodalumab was 4 weeks – about twice as fast as for ustekinumab. Rates of static Physician’s Global Assessment (sPGA) scores of 0 or 1 (clear or almost clear skin) also were significantly higher for brodalumab, compared with placebo (P less than .001).

Mild to moderate candidiasis was more common during induction of brodalumab, compared with ustekinumab or placebo, underscoring the role of interleukin-17A in microbial surveillance, Dr. Lebwohl and his associates pointed out. They estimated that 1-1.3 serious infections occurred for every 100 patient-years of exposure to brodalumab, through 52 weeks.

The investigators reported but did not comment on the suicides, stating only that the study populations were large enough to assess common adverse events but “may have been inadequate for the detection of rare adverse events, which would require longer follow-up of large numbers of patients to provide a full understanding of the safety profile of brodalumab.”

Ustekinumab is marketed as Stelara.

Amgen funded the AMAGINE-2 and AMAGINE-3 studies. Dr. Lebwohl reported having received grant support from Amgen, AbbVie, Janssen Biotech, UCB Pharma, Pfizer, Celgene, Eli Lilly, and Novartis outside the submitted work. Twenty-four coauthors reported grant support or personal fees from Amgen, Abbvie, Merck, Janssen, and several other pharmaceutical companies. The other investigators declared no competing interests.

Brodalumab met all primary endpoints against its first-in-class rival, ustekinumab, and against placebo in two phase III trials of more than 3,700 patients with moderate to severe plaque psoriasis, investigators reported in the New England Journal of Medicine.

The results of the two studies, AMAGINE-2 and AMAGINE-3, were published on Sept. 30 (N Eng J Med. 2015;373:1318-28).

“The data for brodalumab are the best data we’ve seen. It literally is twice as effective at achieving PASI [Psoriasis Area Severity Index] 100 as ustekinumab, which is a spectacular drug,” lead investigator Dr. Mark Lebwohl said in an interview. “More than two-thirds of patients achieved PASI 90. We’ve never seen data like this before,” said Dr. Lebwohl, professor and chairman of the department of dermatology at Icahn School of Medicine at Mount Sinai, New York.

Dermatologists and patients have closely followed brodalumab, an investigational interleukin-17 receptor A inhibitor, which, in March 2015, was reported to have doubled the PASI 100 response rate of ustekinumab in the AMAGINE-2 trial. But 2 months later, Amgen pulled funding and ended its partnership with AstraZeneca on the biologic in the wake of suicides of two patients who had recently completed brodalumab treatment. At the time, Amgen stated that it was concerned that brodalumab would receive restrictive labeling related to suicidal ideation and behavior. An Amgen spokeswoman on Sept. 29 declined to elaborate.

On Sept. 1, however, Valeant Pharmaceuticals announced that it was partnering with AstraZeneca to continue with plans to develop and commercialize brodalumab and that regulatory submissions in the United States and the European Union were planned for the 4th quarter of 2015.

In the interview, Dr. Lebwohl said he did not know of a mechanism by which blocking the IL-17 receptor might increase the risk of depression or suicide. “But psoriasis is certainly associated with depression,” he added. “Two out of more than 3,700 patients committed suicide over more than a year, and that could certainly be attributable to the depression associated with the underlying skin disease.”

AMAGINE-2 and AMAGINE-3 were replicate phase III, double-blind, randomized, controlled trials of 3,712 patients with moderate to severe plaque psoriasis. In the two studies, week 12 PASI 75 rates were about 85% with 210 mg of brodalumab, about 68% for 140 mg of brodalumab, and 6%-8% for placebo (P less than .001). Moreover, week 12 PASI 100 response rates with 210 mg of brodalumab were 37% and 44%, compared with 19% and 22% for ustekinumab (P less than .001), the investigators reported.

Median time to PASI 75 on 210 mg of brodalumab was 4 weeks – about twice as fast as for ustekinumab. Rates of static Physician’s Global Assessment (sPGA) scores of 0 or 1 (clear or almost clear skin) also were significantly higher for brodalumab, compared with placebo (P less than .001).

Mild to moderate candidiasis was more common during induction of brodalumab, compared with ustekinumab or placebo, underscoring the role of interleukin-17A in microbial surveillance, Dr. Lebwohl and his associates pointed out. They estimated that 1-1.3 serious infections occurred for every 100 patient-years of exposure to brodalumab, through 52 weeks.

The investigators reported but did not comment on the suicides, stating only that the study populations were large enough to assess common adverse events but “may have been inadequate for the detection of rare adverse events, which would require longer follow-up of large numbers of patients to provide a full understanding of the safety profile of brodalumab.”

Ustekinumab is marketed as Stelara.

Amgen funded the AMAGINE-2 and AMAGINE-3 studies. Dr. Lebwohl reported having received grant support from Amgen, AbbVie, Janssen Biotech, UCB Pharma, Pfizer, Celgene, Eli Lilly, and Novartis outside the submitted work. Twenty-four coauthors reported grant support or personal fees from Amgen, Abbvie, Merck, Janssen, and several other pharmaceutical companies. The other investigators declared no competing interests.

Inhibition of interleukin-17A with secukinumab gave half of psoriatic arthritis patients treated with either a low or high dose of the monoclonal antibody at least 20% improvement in the American College of Rheumatology response criteria, according to investigators in the FUTURE 1 trial published Sept. 30 in the New England Journal of Medicine.

A team of researchers led by Dr. Philip J. Mease of the Swedish Medical Center and the University of Washington, both in Seattle, assessed the efficacy of secukinumab by measuring the proportion of patients from baseline to week 24 who attained an ACR20 level of response, defined as 20% improvement in the number of tender joints (from an analysis of 78 joints), in the number of swollen joints (from an analysis of 76 joints), and in at least three of five other important domains.

Dr. Mease and his associates examined 606 patients in this double-blind, phase III study and randomly assigned them in a 1:1:1 ratio to receive IV secukinumab 10 mg/kg at weeks 0, 2, and 4, followed by subcutaneous secukinumab at a dose of either 150 mg or 75 mg every 4 weeks, or placebo.

They found that ACR20 response rates at week 24 were significantly higher in the group receiving secukinumab at doses of 150 mg (50.0%) and 75 mg (50.5%) than in those receiving placebo (17.3%). There also was significantly less radiographic progression, as measured by the change from baseline on the van der Heijde–modified total Sharp score at week 24, in the secukinumab groups, compared with patients in the placebo group. The researchers, however, also noted that infections were more common in the secukinumab groups and that four patients in the secukinumab groups had a stroke.

Read the full article here (N Engl J Med. 2015 Sept. 30;373:1329-39. doi: 10.1056/NEJMoa1412679).

mbock@frontlinemedcom.com

Inhibition of interleukin-17A with secukinumab gave half of psoriatic arthritis patients treated with either a low or high dose of the monoclonal antibody at least 20% improvement in the American College of Rheumatology response criteria, according to investigators in the FUTURE 1 trial published Sept. 30 in the New England Journal of Medicine.

A team of researchers led by Dr. Philip J. Mease of the Swedish Medical Center and the University of Washington, both in Seattle, assessed the efficacy of secukinumab by measuring the proportion of patients from baseline to week 24 who attained an ACR20 level of response, defined as 20% improvement in the number of tender joints (from an analysis of 78 joints), in the number of swollen joints (from an analysis of 76 joints), and in at least three of five other important domains.

Dr. Mease and his associates examined 606 patients in this double-blind, phase III study and randomly assigned them in a 1:1:1 ratio to receive IV secukinumab 10 mg/kg at weeks 0, 2, and 4, followed by subcutaneous secukinumab at a dose of either 150 mg or 75 mg every 4 weeks, or placebo.

They found that ACR20 response rates at week 24 were significantly higher in the group receiving secukinumab at doses of 150 mg (50.0%) and 75 mg (50.5%) than in those receiving placebo (17.3%). There also was significantly less radiographic progression, as measured by the change from baseline on the van der Heijde–modified total Sharp score at week 24, in the secukinumab groups, compared with patients in the placebo group. The researchers, however, also noted that infections were more common in the secukinumab groups and that four patients in the secukinumab groups had a stroke.

Read the full article here (N Engl J Med. 2015 Sept. 30;373:1329-39. doi: 10.1056/NEJMoa1412679).

mbock@frontlinemedcom.com

Inhibition of interleukin-17A with secukinumab gave half of psoriatic arthritis patients treated with either a low or high dose of the monoclonal antibody at least 20% improvement in the American College of Rheumatology response criteria, according to investigators in the FUTURE 1 trial published Sept. 30 in the New England Journal of Medicine.

A team of researchers led by Dr. Philip J. Mease of the Swedish Medical Center and the University of Washington, both in Seattle, assessed the efficacy of secukinumab by measuring the proportion of patients from baseline to week 24 who attained an ACR20 level of response, defined as 20% improvement in the number of tender joints (from an analysis of 78 joints), in the number of swollen joints (from an analysis of 76 joints), and in at least three of five other important domains.

Dr. Mease and his associates examined 606 patients in this double-blind, phase III study and randomly assigned them in a 1:1:1 ratio to receive IV secukinumab 10 mg/kg at weeks 0, 2, and 4, followed by subcutaneous secukinumab at a dose of either 150 mg or 75 mg every 4 weeks, or placebo.

They found that ACR20 response rates at week 24 were significantly higher in the group receiving secukinumab at doses of 150 mg (50.0%) and 75 mg (50.5%) than in those receiving placebo (17.3%). There also was significantly less radiographic progression, as measured by the change from baseline on the van der Heijde–modified total Sharp score at week 24, in the secukinumab groups, compared with patients in the placebo group. The researchers, however, also noted that infections were more common in the secukinumab groups and that four patients in the secukinumab groups had a stroke.

Read the full article here (N Engl J Med. 2015 Sept. 30;373:1329-39. doi: 10.1056/NEJMoa1412679).

mbock@frontlinemedcom.com

The CADMUS trial showed improvements in moderate to severe psoriasis in adolescent patients 12 years or older treated with ustekinumab, a study showed.

Treatment of psoriasis in pediatric patients is complicated by the limited number of approved treatments, despite approximately one-third of patients developing psoriasis before the age of 20 years. A human monoclonal antibody that targets the p40 subunit of interleukin-12/23, known as ustekinumab, was found to be effective and safe in moderate to severe psoriasis in adults.

Dr. Ian Landells of Memorial University of Newfoundland in St. John’s and his colleagues presented the results of the CADMUS trial, a randomized phase III trial of ustekinumab for active psoriasis in patients aged 12-17 years (J Am Acad Dermatol. 2015;73:594-603).

Lori Farmer/Frontline Medical News

Patients aged 12-17 years with moderate to severe plaque psoriasis as defined by a Physician’s Global Assessment (PGA) score of greater than or equal to 3, a Psoriasis Area and Severity Index (PASI) of greater than or equal to 12, or 10% or more of body surface area involved for at least 6 months were included in the study.

The investigators conducted a multicenter, double-blind placebo-controlled trial with patients randomly assigned to weight-based standard dosing (SD) or weight-based half-standard dosing (HSD) at weeks 0, 4, and 16, then every 12 weeks until week 40. Conversely, participants could receive placebo at weeks 0 and 4 with crossover at week 12 and 16, then every 12 weeks until week 40 with either SD or HSD. Early escape to topical steroids at week 8 to week 12 for patients with a PASI increase to more than 50% above baseline was considered.

The primary endpoint of the study was the proportion of patients who achieved a PGA 0/1 by week 12. Secondary endpoints included the proportion of patients with 75% improvement by PASI (PASI 75) and 90% improvement by PASI (PASI 90) at 12 weeks, and change in the Children’s Dermatology Life Quality Index (CDLQI) at 12 weeks.

Between March 2010 and January 2014, 110 patients were included in the study: 36 randomly assigned to weight-based SD ustekinumab, 37 to weight-based HSD, and 37 to placebo, with 18 participants crossing over to SD and 19 participants crossing over to HSD. One participant each from the HSD and SD achieved early escape at 8 weeks. A total of nine participants (8%) discontinued the study because of adverse events (n = 3), death in an automobile accident (n = 1), or an unsatisfactory response (n = 5).

After 12 weeks, there were significantly more participants receiving either SD (69%) or HSD (68%) achieving a PGA of 0/1 vs. placebo (5%, P less than .001 for both doses). About one-third of the treatment participants achieved a PGA of 0/1 by week 4. Likewise, in the treatment group, significantly more participants achieved a PGA of 0 by week 12 (SD, 47%; HSD, 32%; placebo, 3%; P less than .001 for both doses).

When treatment response by PASI was assessed, a PASI 75 and PASI 90 were achieved significantly more often in the treatment groups (P less than .001 for both) than among controls. A PASI score of 0 (cleared) was achieved in 39% of the SD group and 22% of the HSD group vs. 3% with placebo (P less than .001 and P = .014, respectively).

Participants treated with ustekinumab demonstrated improvements in quality of life that were maintained at 52 weeks.

At week 12, 44% of the SD group, 51% of the HSD group, and 57% of the placebo group reported one or more adverse events. At the conclusion of the study at week 60, 82% of the participants had reported adverse events. Most of the adverse events were under the category of infections and infestations, which the authors noted were consistent with those observed in adults treated with ustekinumab.

Dr. Landells and his colleagues wrote, “Patients in both the HSD and SD ustekinumab groups experienced robust and clinically meaningful improvements in disease activity.”

The study was funded by Janssen Research and Development. The authors reported multiple financial disclosures.

The CADMUS trial showed improvements in moderate to severe psoriasis in adolescent patients 12 years or older treated with ustekinumab, a study showed.

Treatment of psoriasis in pediatric patients is complicated by the limited number of approved treatments, despite approximately one-third of patients developing psoriasis before the age of 20 years. A human monoclonal antibody that targets the p40 subunit of interleukin-12/23, known as ustekinumab, was found to be effective and safe in moderate to severe psoriasis in adults.

Dr. Ian Landells of Memorial University of Newfoundland in St. John’s and his colleagues presented the results of the CADMUS trial, a randomized phase III trial of ustekinumab for active psoriasis in patients aged 12-17 years (J Am Acad Dermatol. 2015;73:594-603).

Lori Farmer/Frontline Medical News

Patients aged 12-17 years with moderate to severe plaque psoriasis as defined by a Physician’s Global Assessment (PGA) score of greater than or equal to 3, a Psoriasis Area and Severity Index (PASI) of greater than or equal to 12, or 10% or more of body surface area involved for at least 6 months were included in the study.

The investigators conducted a multicenter, double-blind placebo-controlled trial with patients randomly assigned to weight-based standard dosing (SD) or weight-based half-standard dosing (HSD) at weeks 0, 4, and 16, then every 12 weeks until week 40. Conversely, participants could receive placebo at weeks 0 and 4 with crossover at week 12 and 16, then every 12 weeks until week 40 with either SD or HSD. Early escape to topical steroids at week 8 to week 12 for patients with a PASI increase to more than 50% above baseline was considered.

The primary endpoint of the study was the proportion of patients who achieved a PGA 0/1 by week 12. Secondary endpoints included the proportion of patients with 75% improvement by PASI (PASI 75) and 90% improvement by PASI (PASI 90) at 12 weeks, and change in the Children’s Dermatology Life Quality Index (CDLQI) at 12 weeks.

Between March 2010 and January 2014, 110 patients were included in the study: 36 randomly assigned to weight-based SD ustekinumab, 37 to weight-based HSD, and 37 to placebo, with 18 participants crossing over to SD and 19 participants crossing over to HSD. One participant each from the HSD and SD achieved early escape at 8 weeks. A total of nine participants (8%) discontinued the study because of adverse events (n = 3), death in an automobile accident (n = 1), or an unsatisfactory response (n = 5).

After 12 weeks, there were significantly more participants receiving either SD (69%) or HSD (68%) achieving a PGA of 0/1 vs. placebo (5%, P less than .001 for both doses). About one-third of the treatment participants achieved a PGA of 0/1 by week 4. Likewise, in the treatment group, significantly more participants achieved a PGA of 0 by week 12 (SD, 47%; HSD, 32%; placebo, 3%; P less than .001 for both doses).

When treatment response by PASI was assessed, a PASI 75 and PASI 90 were achieved significantly more often in the treatment groups (P less than .001 for both) than among controls. A PASI score of 0 (cleared) was achieved in 39% of the SD group and 22% of the HSD group vs. 3% with placebo (P less than .001 and P = .014, respectively).

Participants treated with ustekinumab demonstrated improvements in quality of life that were maintained at 52 weeks.

At week 12, 44% of the SD group, 51% of the HSD group, and 57% of the placebo group reported one or more adverse events. At the conclusion of the study at week 60, 82% of the participants had reported adverse events. Most of the adverse events were under the category of infections and infestations, which the authors noted were consistent with those observed in adults treated with ustekinumab.

Dr. Landells and his colleagues wrote, “Patients in both the HSD and SD ustekinumab groups experienced robust and clinically meaningful improvements in disease activity.”

The study was funded by Janssen Research and Development. The authors reported multiple financial disclosures.

The CADMUS trial showed improvements in moderate to severe psoriasis in adolescent patients 12 years or older treated with ustekinumab, a study showed.

Treatment of psoriasis in pediatric patients is complicated by the limited number of approved treatments, despite approximately one-third of patients developing psoriasis before the age of 20 years. A human monoclonal antibody that targets the p40 subunit of interleukin-12/23, known as ustekinumab, was found to be effective and safe in moderate to severe psoriasis in adults.

Dr. Ian Landells of Memorial University of Newfoundland in St. John’s and his colleagues presented the results of the CADMUS trial, a randomized phase III trial of ustekinumab for active psoriasis in patients aged 12-17 years (J Am Acad Dermatol. 2015;73:594-603).

Lori Farmer/Frontline Medical News

Patients aged 12-17 years with moderate to severe plaque psoriasis as defined by a Physician’s Global Assessment (PGA) score of greater than or equal to 3, a Psoriasis Area and Severity Index (PASI) of greater than or equal to 12, or 10% or more of body surface area involved for at least 6 months were included in the study.

The investigators conducted a multicenter, double-blind placebo-controlled trial with patients randomly assigned to weight-based standard dosing (SD) or weight-based half-standard dosing (HSD) at weeks 0, 4, and 16, then every 12 weeks until week 40. Conversely, participants could receive placebo at weeks 0 and 4 with crossover at week 12 and 16, then every 12 weeks until week 40 with either SD or HSD. Early escape to topical steroids at week 8 to week 12 for patients with a PASI increase to more than 50% above baseline was considered.

The primary endpoint of the study was the proportion of patients who achieved a PGA 0/1 by week 12. Secondary endpoints included the proportion of patients with 75% improvement by PASI (PASI 75) and 90% improvement by PASI (PASI 90) at 12 weeks, and change in the Children’s Dermatology Life Quality Index (CDLQI) at 12 weeks.

Between March 2010 and January 2014, 110 patients were included in the study: 36 randomly assigned to weight-based SD ustekinumab, 37 to weight-based HSD, and 37 to placebo, with 18 participants crossing over to SD and 19 participants crossing over to HSD. One participant each from the HSD and SD achieved early escape at 8 weeks. A total of nine participants (8%) discontinued the study because of adverse events (n = 3), death in an automobile accident (n = 1), or an unsatisfactory response (n = 5).

After 12 weeks, there were significantly more participants receiving either SD (69%) or HSD (68%) achieving a PGA of 0/1 vs. placebo (5%, P less than .001 for both doses). About one-third of the treatment participants achieved a PGA of 0/1 by week 4. Likewise, in the treatment group, significantly more participants achieved a PGA of 0 by week 12 (SD, 47%; HSD, 32%; placebo, 3%; P less than .001 for both doses).

When treatment response by PASI was assessed, a PASI 75 and PASI 90 were achieved significantly more often in the treatment groups (P less than .001 for both) than among controls. A PASI score of 0 (cleared) was achieved in 39% of the SD group and 22% of the HSD group vs. 3% with placebo (P less than .001 and P = .014, respectively).

Participants treated with ustekinumab demonstrated improvements in quality of life that were maintained at 52 weeks.

At week 12, 44% of the SD group, 51% of the HSD group, and 57% of the placebo group reported one or more adverse events. At the conclusion of the study at week 60, 82% of the participants had reported adverse events. Most of the adverse events were under the category of infections and infestations, which the authors noted were consistent with those observed in adults treated with ustekinumab.

Dr. Landells and his colleagues wrote, “Patients in both the HSD and SD ustekinumab groups experienced robust and clinically meaningful improvements in disease activity.”

The study was funded by Janssen Research and Development. The authors reported multiple financial disclosures.

Self-reported psoriasis more than doubled the odds of major depression, even after accounting for demographic factors and comorbidities, reported the authors of a study that used data from the National Health and Nutrition Examination Survey.

In addition, depressive symptoms adversely affected the work and social lives of psoriasis patients in this first-in-kind study, said Dr. Brandon Cohen and his associates of the department of dermatology, New York University. “The risk of major depression was not associated with the self-reported degree of psoriasis. Therefore, our study supports that all patients with psoriasis, regardless of severity, are at risk for depressive symptoms and may benefit from depression screening,” they wrote. The study was published online on Sept. 30 in JAMA Dermatology (2015 Sep 30. doi: 10.1001/jamadermatol.2015.3605).

Courtesy of the Centers for Disease Control and Prevention (CDC)

Psoriasis is known to increase the risk of major depression, as well as anxiety disorders, substance abuse, and suicidal ideation. To better understand whether disease severity or comorbidities affect the psoriasis-depression link, the researchers analyzed self-reported health data from 12,382 individuals who had responded to the National Health and Nutrition Examination Survey between 2009 and 2012. The investigators defined major depression as a score of at least 10 on the 27-point Patient Health Questionnaire-9 (PHQ-9). Psoriasis was self-reported, and some psoriasis patients were also asked to rate the severity of their skin disease.

After adjusting for factors such as age, sex, race, and history of myocardial infarction, stroke, and diabetes, the 351 individuals with psoriasis had more than twice the odds of major depression, compared with respondents without psoriasis (odds ratio, 2.09; 95% confidence interval, 1.41-3.11; P less than .001). Furthermore, the average PHQ-9 score among psoriasis patients was significantly higher than that among other respondents (4.54 vs. 3.22; P less than .001).

Neither severity of skin disease nor history of MI or stroke affected the relationship between psoriasis and depression. “The psychiatric burden of psoriasis may be more closely tied to patients’ perception of the social response to their appearance than objective disease severity,” the investigators said. They noted that as far as they know, this is the first study to use a nationally representative sample of patients to evaluate the association between psoriasis and major depression.

The investigators reported no funding sources and declared no competing interests.

Self-reported psoriasis more than doubled the odds of major depression, even after accounting for demographic factors and comorbidities, reported the authors of a study that used data from the National Health and Nutrition Examination Survey.

In addition, depressive symptoms adversely affected the work and social lives of psoriasis patients in this first-in-kind study, said Dr. Brandon Cohen and his associates of the department of dermatology, New York University. “The risk of major depression was not associated with the self-reported degree of psoriasis. Therefore, our study supports that all patients with psoriasis, regardless of severity, are at risk for depressive symptoms and may benefit from depression screening,” they wrote. The study was published online on Sept. 30 in JAMA Dermatology (2015 Sep 30. doi: 10.1001/jamadermatol.2015.3605).

Courtesy of the Centers for Disease Control and Prevention (CDC)

Psoriasis is known to increase the risk of major depression, as well as anxiety disorders, substance abuse, and suicidal ideation. To better understand whether disease severity or comorbidities affect the psoriasis-depression link, the researchers analyzed self-reported health data from 12,382 individuals who had responded to the National Health and Nutrition Examination Survey between 2009 and 2012. The investigators defined major depression as a score of at least 10 on the 27-point Patient Health Questionnaire-9 (PHQ-9). Psoriasis was self-reported, and some psoriasis patients were also asked to rate the severity of their skin disease.

After adjusting for factors such as age, sex, race, and history of myocardial infarction, stroke, and diabetes, the 351 individuals with psoriasis had more than twice the odds of major depression, compared with respondents without psoriasis (odds ratio, 2.09; 95% confidence interval, 1.41-3.11; P less than .001). Furthermore, the average PHQ-9 score among psoriasis patients was significantly higher than that among other respondents (4.54 vs. 3.22; P less than .001).

Neither severity of skin disease nor history of MI or stroke affected the relationship between psoriasis and depression. “The psychiatric burden of psoriasis may be more closely tied to patients’ perception of the social response to their appearance than objective disease severity,” the investigators said. They noted that as far as they know, this is the first study to use a nationally representative sample of patients to evaluate the association between psoriasis and major depression.

The investigators reported no funding sources and declared no competing interests.

Self-reported psoriasis more than doubled the odds of major depression, even after accounting for demographic factors and comorbidities, reported the authors of a study that used data from the National Health and Nutrition Examination Survey.

In addition, depressive symptoms adversely affected the work and social lives of psoriasis patients in this first-in-kind study, said Dr. Brandon Cohen and his associates of the department of dermatology, New York University. “The risk of major depression was not associated with the self-reported degree of psoriasis. Therefore, our study supports that all patients with psoriasis, regardless of severity, are at risk for depressive symptoms and may benefit from depression screening,” they wrote. The study was published online on Sept. 30 in JAMA Dermatology (2015 Sep 30. doi: 10.1001/jamadermatol.2015.3605).

Courtesy of the Centers for Disease Control and Prevention (CDC)

Psoriasis is known to increase the risk of major depression, as well as anxiety disorders, substance abuse, and suicidal ideation. To better understand whether disease severity or comorbidities affect the psoriasis-depression link, the researchers analyzed self-reported health data from 12,382 individuals who had responded to the National Health and Nutrition Examination Survey between 2009 and 2012. The investigators defined major depression as a score of at least 10 on the 27-point Patient Health Questionnaire-9 (PHQ-9). Psoriasis was self-reported, and some psoriasis patients were also asked to rate the severity of their skin disease.

After adjusting for factors such as age, sex, race, and history of myocardial infarction, stroke, and diabetes, the 351 individuals with psoriasis had more than twice the odds of major depression, compared with respondents without psoriasis (odds ratio, 2.09; 95% confidence interval, 1.41-3.11; P less than .001). Furthermore, the average PHQ-9 score among psoriasis patients was significantly higher than that among other respondents (4.54 vs. 3.22; P less than .001).

Neither severity of skin disease nor history of MI or stroke affected the relationship between psoriasis and depression. “The psychiatric burden of psoriasis may be more closely tied to patients’ perception of the social response to their appearance than objective disease severity,” the investigators said. They noted that as far as they know, this is the first study to use a nationally representative sample of patients to evaluate the association between psoriasis and major depression.

The investigators reported no funding sources and declared no competing interests.

Clinical diagnosis of nail psoriasis may be difficult, as many of its symptoms are seen in other nail disorders. To ensure accurate diagnosis, it is important to recognize the characteristic signs of nail psoriasis and clarify which part of the nail matrix is affected. Dr. Antonella Tosti discusses common symptoms of nail psoriasis and provides treatment and nail care recommendations for patients. She also notes that psoriasis of the nails should raise suspicion of possible joint involvement.

The psoriasis audiocast series is created in collaboration with Cutis^® and the National Psoriasis Foundation^®.

Clinical diagnosis of nail psoriasis may be difficult, as many of its symptoms are seen in other nail disorders. To ensure accurate diagnosis, it is important to recognize the characteristic signs of nail psoriasis and clarify which part of the nail matrix is affected. Dr. Antonella Tosti discusses common symptoms of nail psoriasis and provides treatment and nail care recommendations for patients. She also notes that psoriasis of the nails should raise suspicion of possible joint involvement.

The psoriasis audiocast series is created in collaboration with Cutis^® and the National Psoriasis Foundation^®.

Clinical diagnosis of nail psoriasis may be difficult, as many of its symptoms are seen in other nail disorders. To ensure accurate diagnosis, it is important to recognize the characteristic signs of nail psoriasis and clarify which part of the nail matrix is affected. Dr. Antonella Tosti discusses common symptoms of nail psoriasis and provides treatment and nail care recommendations for patients. She also notes that psoriasis of the nails should raise suspicion of possible joint involvement.

The psoriasis audiocast series is created in collaboration with Cutis^® and the National Psoriasis Foundation^®.

Dermatologists should screen psoriasis patients for tuberculosis (TB) and hepatitis B virus (HBV) before beginning treatment with tumor necrosis factor (TNF) inhibitors or biologics, according to Jashin J. Wu, MD, Director of the Psoriasis Clinic, Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, California, at the 2015 Summer Academy Meeting of the American Academy of Dermatology. Dr. Wu provided 10 psoriasis pearls in 10 minutes. Among them he reviewed important screenings for psoriasis patients.

The National Psoriasis Foundation’s consensus statement on screening for latent TB infection in patients with psoriasis treated with systemic and biologic agents (J Am Acad Dermatol. 2008;59:209-217) indicated that chronic immunosuppression is a known risk factor for allowing latent TB to transform into active TB. Therefore, immunosuppressive and immunomodulatory therapies for psoriasis and psoriatic arthritis may be associated with an increased rate of active TB in some patients receiving these therapies. The consensus statement reported, “It is, therefore, of utmost importance to appropriately screen all patients for latent TB infection prior to initiating any immunologic therapy. Delaying immunologic therapy until latent TB infection prophylaxis is completed is preferable.”

When screening for tuberculosis, Dr. Wu recommends the IFN-γ release assay instead of the purified protein derivative (tuberculin)(PPD) test because it is more sensitive and more specific than the PPD in diagnosing latent TB infection in immunocompetent individuals. Additionally, Dr. Wu reports that the IFN-γ release assay is more specific than the PPD in those who have received the BCG vaccine and is more convenient for patients.

For patients who may receive TNF inhibitors, Dr. Wu recommends screening for HBV using triple serology testing: hepatitis B surface antigen, hepatitis B surface antibody, and hepatitis B core antibody. He also recommends this screening for patients who may be on biologics including ustekinumab and secukinumab. If the patient is at risk for reactivation of HBV, dermatologists should check liver function tests, hepatitis B surface antibody, hepatitis B core e antigen, and HBV DNA counts. Routine follow-up with testing for reactivation should continue for at least 6 months after the TNF inhibitor is discontinued. If patients have chronic HBV and biologics are considered, etanercept is recommended as first-line therapy.

Dermatologists should screen psoriasis patients for tuberculosis (TB) and hepatitis B virus (HBV) before beginning treatment with tumor necrosis factor (TNF) inhibitors or biologics, according to Jashin J. Wu, MD, Director of the Psoriasis Clinic, Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, California, at the 2015 Summer Academy Meeting of the American Academy of Dermatology. Dr. Wu provided 10 psoriasis pearls in 10 minutes. Among them he reviewed important screenings for psoriasis patients.

The National Psoriasis Foundation’s consensus statement on screening for latent TB infection in patients with psoriasis treated with systemic and biologic agents (J Am Acad Dermatol. 2008;59:209-217) indicated that chronic immunosuppression is a known risk factor for allowing latent TB to transform into active TB. Therefore, immunosuppressive and immunomodulatory therapies for psoriasis and psoriatic arthritis may be associated with an increased rate of active TB in some patients receiving these therapies. The consensus statement reported, “It is, therefore, of utmost importance to appropriately screen all patients for latent TB infection prior to initiating any immunologic therapy. Delaying immunologic therapy until latent TB infection prophylaxis is completed is preferable.”

When screening for tuberculosis, Dr. Wu recommends the IFN-γ release assay instead of the purified protein derivative (tuberculin)(PPD) test because it is more sensitive and more specific than the PPD in diagnosing latent TB infection in immunocompetent individuals. Additionally, Dr. Wu reports that the IFN-γ release assay is more specific than the PPD in those who have received the BCG vaccine and is more convenient for patients.

For patients who may receive TNF inhibitors, Dr. Wu recommends screening for HBV using triple serology testing: hepatitis B surface antigen, hepatitis B surface antibody, and hepatitis B core antibody. He also recommends this screening for patients who may be on biologics including ustekinumab and secukinumab. If the patient is at risk for reactivation of HBV, dermatologists should check liver function tests, hepatitis B surface antibody, hepatitis B core e antigen, and HBV DNA counts. Routine follow-up with testing for reactivation should continue for at least 6 months after the TNF inhibitor is discontinued. If patients have chronic HBV and biologics are considered, etanercept is recommended as first-line therapy.

Dermatologists should screen psoriasis patients for tuberculosis (TB) and hepatitis B virus (HBV) before beginning treatment with tumor necrosis factor (TNF) inhibitors or biologics, according to Jashin J. Wu, MD, Director of the Psoriasis Clinic, Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, California, at the 2015 Summer Academy Meeting of the American Academy of Dermatology. Dr. Wu provided 10 psoriasis pearls in 10 minutes. Among them he reviewed important screenings for psoriasis patients.

The National Psoriasis Foundation’s consensus statement on screening for latent TB infection in patients with psoriasis treated with systemic and biologic agents (J Am Acad Dermatol. 2008;59:209-217) indicated that chronic immunosuppression is a known risk factor for allowing latent TB to transform into active TB. Therefore, immunosuppressive and immunomodulatory therapies for psoriasis and psoriatic arthritis may be associated with an increased rate of active TB in some patients receiving these therapies. The consensus statement reported, “It is, therefore, of utmost importance to appropriately screen all patients for latent TB infection prior to initiating any immunologic therapy. Delaying immunologic therapy until latent TB infection prophylaxis is completed is preferable.”

When screening for tuberculosis, Dr. Wu recommends the IFN-γ release assay instead of the purified protein derivative (tuberculin)(PPD) test because it is more sensitive and more specific than the PPD in diagnosing latent TB infection in immunocompetent individuals. Additionally, Dr. Wu reports that the IFN-γ release assay is more specific than the PPD in those who have received the BCG vaccine and is more convenient for patients.

For patients who may receive TNF inhibitors, Dr. Wu recommends screening for HBV using triple serology testing: hepatitis B surface antigen, hepatitis B surface antibody, and hepatitis B core antibody. He also recommends this screening for patients who may be on biologics including ustekinumab and secukinumab. If the patient is at risk for reactivation of HBV, dermatologists should check liver function tests, hepatitis B surface antibody, hepatitis B core e antigen, and HBV DNA counts. Routine follow-up with testing for reactivation should continue for at least 6 months after the TNF inhibitor is discontinued. If patients have chronic HBV and biologics are considered, etanercept is recommended as first-line therapy.

Efforts underway to tailor psoriatic arthritis treatments to the various tissues involved in the pathogenesis of the disease could optimize therapeutic approaches, Dr. Iain McInnes said at the annual Perspectives in Rheumatic Diseases held by Global Academy for Medical Education.

“Psoriatic arthritis [PsA] is a disease whose treatment is evolving quickly, ” added Dr. McInnes, professor of medicine and director of the Institute of Infection, Immunity, and Inflammation at the University of Glasgow (Scotland). “We have new ideas about pathogenesis, emerging studies that inform the best strategic approach to disease management, including potential value in a treat-to-target approach, and new therapeutics that offer a range of options to allow us to optimize treatment.”

He pointed to recent evidence for a diverse pathogenesis of PsA subtypes. Synovial membranes in PsA have high levels of tumor necrosis factor (TNF)-alpha, while resident populations of interleukin (IL)-23 receptor–positive T cells are found in entheses and IL-17 is abundant in psoriatic lesions. Genome-wide association studies have underscored the role of the IL-23 and IL-17 cytokine axis, while other work has implicated Th17 cytokines in mesenchymal tissue changes.

Although drug development efforts have typically viewed rheumatoid arthritis and PsA as homogeneous, “we can appreciate the extent of articular, entheseal, and cutaneous involvement, and look to tailor therapies accordingly,” Dr. McInnes said.

So what will the next decade look like for PsA? Therapy will center around TNF-alpha inhibitors, new cytokine pathways, and small-molecule inhibitors, according to Dr. McInnes. While anti-TNF agents are not universally tolerated or effective, their “well-established safety profile” and positive effects on American College of Rheumatology response criteria and radiographic endpoints generally outweigh risks of infection and problems with decreasing long-term drug survival, he said. These agents also can improve disease activity, skin symptoms, physical function, fatigue, overall quality of life, enthesitis, and dactylitis, he noted.

Other recent additions to the PsA arsenal include the IL-12/IL-23 inhibitor ustekinumab (Stelara), which in the PSUMMIT 1 and 2 trials was associated with decreased rates of radiographic progression and dose-dependent improvements in enthesitis, Dr. McInnes said. The phosphodiesterase-4 inhibitor apremilast (Otezla) was associated with significantly better ACR 20 response at week 16 and significantly greater improvements in Maastricht Ankylosing Spondylitis Enthesis Score and measures of dactylitis at week 24 of the PALACE trials. Most recently, in the FUTURE1 and FUTURE2 trials, the IL-17A inhibitor secukinumab (Cosentyx) beat placebo in terms of ACR 20, ACR 50, ACR 70, resolution of dactylitis and enthesitis, and radiographic measures of disease progression.

The availability of effective biologics raises the possibility of a treat-to-target approach geared toward clinical remission or low disease activity, Dr. McInnes concluded. “Targets for low disease activity in PsA are now available. Composite measures of disease activity, such as minimal disease activity (MDA), encompass all clinically important aspects of PsA,” he emphasized. While studies still need to pinpoint the best therapeutic pathways for disease subtypes, the first treat-to-target study of PsA found that tailoring therapy based on remission or minimal disease activity led to significantly better ACR 20, ACR 50, and ACR 70 responses at week 48, compared with standard care, he noted.

Dr. McInnes reported receiving research funding or honoraria from Novartis, Janssen, AbbVie, UCB, Pfizer, and MSD Pharmaceuticals, all of which make medications for rheumatic diseases. Global Academy for Medical Education and this news organization are owned by the same parent company.

Efforts underway to tailor psoriatic arthritis treatments to the various tissues involved in the pathogenesis of the disease could optimize therapeutic approaches, Dr. Iain McInnes said at the annual Perspectives in Rheumatic Diseases held by Global Academy for Medical Education.

“Psoriatic arthritis [PsA] is a disease whose treatment is evolving quickly, ” added Dr. McInnes, professor of medicine and director of the Institute of Infection, Immunity, and Inflammation at the University of Glasgow (Scotland). “We have new ideas about pathogenesis, emerging studies that inform the best strategic approach to disease management, including potential value in a treat-to-target approach, and new therapeutics that offer a range of options to allow us to optimize treatment.”

He pointed to recent evidence for a diverse pathogenesis of PsA subtypes. Synovial membranes in PsA have high levels of tumor necrosis factor (TNF)-alpha, while resident populations of interleukin (IL)-23 receptor–positive T cells are found in entheses and IL-17 is abundant in psoriatic lesions. Genome-wide association studies have underscored the role of the IL-23 and IL-17 cytokine axis, while other work has implicated Th17 cytokines in mesenchymal tissue changes.

Although drug development efforts have typically viewed rheumatoid arthritis and PsA as homogeneous, “we can appreciate the extent of articular, entheseal, and cutaneous involvement, and look to tailor therapies accordingly,” Dr. McInnes said.

So what will the next decade look like for PsA? Therapy will center around TNF-alpha inhibitors, new cytokine pathways, and small-molecule inhibitors, according to Dr. McInnes. While anti-TNF agents are not universally tolerated or effective, their “well-established safety profile” and positive effects on American College of Rheumatology response criteria and radiographic endpoints generally outweigh risks of infection and problems with decreasing long-term drug survival, he said. These agents also can improve disease activity, skin symptoms, physical function, fatigue, overall quality of life, enthesitis, and dactylitis, he noted.

Other recent additions to the PsA arsenal include the IL-12/IL-23 inhibitor ustekinumab (Stelara), which in the PSUMMIT 1 and 2 trials was associated with decreased rates of radiographic progression and dose-dependent improvements in enthesitis, Dr. McInnes said. The phosphodiesterase-4 inhibitor apremilast (Otezla) was associated with significantly better ACR 20 response at week 16 and significantly greater improvements in Maastricht Ankylosing Spondylitis Enthesis Score and measures of dactylitis at week 24 of the PALACE trials. Most recently, in the FUTURE1 and FUTURE2 trials, the IL-17A inhibitor secukinumab (Cosentyx) beat placebo in terms of ACR 20, ACR 50, ACR 70, resolution of dactylitis and enthesitis, and radiographic measures of disease progression.

The availability of effective biologics raises the possibility of a treat-to-target approach geared toward clinical remission or low disease activity, Dr. McInnes concluded. “Targets for low disease activity in PsA are now available. Composite measures of disease activity, such as minimal disease activity (MDA), encompass all clinically important aspects of PsA,” he emphasized. While studies still need to pinpoint the best therapeutic pathways for disease subtypes, the first treat-to-target study of PsA found that tailoring therapy based on remission or minimal disease activity led to significantly better ACR 20, ACR 50, and ACR 70 responses at week 48, compared with standard care, he noted.

Dr. McInnes reported receiving research funding or honoraria from Novartis, Janssen, AbbVie, UCB, Pfizer, and MSD Pharmaceuticals, all of which make medications for rheumatic diseases. Global Academy for Medical Education and this news organization are owned by the same parent company.

Efforts underway to tailor psoriatic arthritis treatments to the various tissues involved in the pathogenesis of the disease could optimize therapeutic approaches, Dr. Iain McInnes said at the annual Perspectives in Rheumatic Diseases held by Global Academy for Medical Education.

“Psoriatic arthritis [PsA] is a disease whose treatment is evolving quickly, ” added Dr. McInnes, professor of medicine and director of the Institute of Infection, Immunity, and Inflammation at the University of Glasgow (Scotland). “We have new ideas about pathogenesis, emerging studies that inform the best strategic approach to disease management, including potential value in a treat-to-target approach, and new therapeutics that offer a range of options to allow us to optimize treatment.”

He pointed to recent evidence for a diverse pathogenesis of PsA subtypes. Synovial membranes in PsA have high levels of tumor necrosis factor (TNF)-alpha, while resident populations of interleukin (IL)-23 receptor–positive T cells are found in entheses and IL-17 is abundant in psoriatic lesions. Genome-wide association studies have underscored the role of the IL-23 and IL-17 cytokine axis, while other work has implicated Th17 cytokines in mesenchymal tissue changes.

Although drug development efforts have typically viewed rheumatoid arthritis and PsA as homogeneous, “we can appreciate the extent of articular, entheseal, and cutaneous involvement, and look to tailor therapies accordingly,” Dr. McInnes said.

So what will the next decade look like for PsA? Therapy will center around TNF-alpha inhibitors, new cytokine pathways, and small-molecule inhibitors, according to Dr. McInnes. While anti-TNF agents are not universally tolerated or effective, their “well-established safety profile” and positive effects on American College of Rheumatology response criteria and radiographic endpoints generally outweigh risks of infection and problems with decreasing long-term drug survival, he said. These agents also can improve disease activity, skin symptoms, physical function, fatigue, overall quality of life, enthesitis, and dactylitis, he noted.

Other recent additions to the PsA arsenal include the IL-12/IL-23 inhibitor ustekinumab (Stelara), which in the PSUMMIT 1 and 2 trials was associated with decreased rates of radiographic progression and dose-dependent improvements in enthesitis, Dr. McInnes said. The phosphodiesterase-4 inhibitor apremilast (Otezla) was associated with significantly better ACR 20 response at week 16 and significantly greater improvements in Maastricht Ankylosing Spondylitis Enthesis Score and measures of dactylitis at week 24 of the PALACE trials. Most recently, in the FUTURE1 and FUTURE2 trials, the IL-17A inhibitor secukinumab (Cosentyx) beat placebo in terms of ACR 20, ACR 50, ACR 70, resolution of dactylitis and enthesitis, and radiographic measures of disease progression.

The availability of effective biologics raises the possibility of a treat-to-target approach geared toward clinical remission or low disease activity, Dr. McInnes concluded. “Targets for low disease activity in PsA are now available. Composite measures of disease activity, such as minimal disease activity (MDA), encompass all clinically important aspects of PsA,” he emphasized. While studies still need to pinpoint the best therapeutic pathways for disease subtypes, the first treat-to-target study of PsA found that tailoring therapy based on remission or minimal disease activity led to significantly better ACR 20, ACR 50, and ACR 70 responses at week 48, compared with standard care, he noted.

Dr. McInnes reported receiving research funding or honoraria from Novartis, Janssen, AbbVie, UCB, Pfizer, and MSD Pharmaceuticals, all of which make medications for rheumatic diseases. Global Academy for Medical Education and this news organization are owned by the same parent company.

Methotrexate use more than doubled the risk of liver enzyme abnormalities but was not tied to serious hepatic outcomes among patients with rheumatic diseases, according to a meta-analysis of 32 randomized, controlled trials.

“Serious liver events were rare, with a suggestion of a trend towards fewer poor liver outcomes,” wrote Dr. Richard Conway of Galway (Ireland) University Hospitals. “The short duration of the included studies and the lack of liver biopsies are limitations, but the available data provide robust evidence for short-term safety” of methotrexate, wrote Dr. Conway and his associates.

Methotrexate is a first-line RA therapy with efficacy in several other inflammatory diseases, but concerns about toxicity have limited its use, the researchers noted. Clinicians have particularly debated its hepatic effects, in part because it can be “exceedingly difficult” to determine if liver disease is preexisting, methotrexate related, or caused by other medications or comorbidities, they said. To better assess the issue, they searched PubMed and the Cochrane Central Register of Controlled Trials for relevant double-blind, randomized, controlled trials published between 1990 and 2014. They found 32 such trials that included 13,177 patients with rheumatoid arthritis, psoriasis, psoriatic arthritis or inflammatory bowel disease (Semin Arthritis Rheum. 2015;45:156-62). Methotrexate use approximately doubled the risk of any adverse hepatic event (relative risk, 2.19; 95% confidence interval, 1.73-2.77) and of major and minor liver enzyme abnormalities (RR, 2.16; 95% CI, 1.67-2.79), but did not increase the risk of liver failure, cirrhosis, or liver-related mortality (RR, 0.12; 95% CI, 0.01-1.09), the investigators reported. “Clinical trials have inherent limitations, including short duration, selection bias, failure to collect information or reports that are not part of a prespecified protocol, and limited power to evaluate rare or unusual reports,” they cautioned. “While meta-analyses help overcome the last of these, the others raise some concern.”

But several other reports align with their results, the researchers noted. In an analysis of methotrexate studies lasting at least 2 years, about 10% of patients developed at least one minor liver enzyme abnormality, but less than 4% stopped methotrexate because of liver toxicity. Other controlled studies did not link methotrexate to severe fibrosis or cirrhosis – even after 4 years of treatment, they added. “It appears likely that serious liver-related complications due to methotrexate may take many years of treatment to manifest,” the investigators concluded.

The researchers reported no funding sources or conflicts of interest.

Methotrexate use more than doubled the risk of liver enzyme abnormalities but was not tied to serious hepatic outcomes among patients with rheumatic diseases, according to a meta-analysis of 32 randomized, controlled trials.

“Serious liver events were rare, with a suggestion of a trend towards fewer poor liver outcomes,” wrote Dr. Richard Conway of Galway (Ireland) University Hospitals. “The short duration of the included studies and the lack of liver biopsies are limitations, but the available data provide robust evidence for short-term safety” of methotrexate, wrote Dr. Conway and his associates.

Methotrexate is a first-line RA therapy with efficacy in several other inflammatory diseases, but concerns about toxicity have limited its use, the researchers noted. Clinicians have particularly debated its hepatic effects, in part because it can be “exceedingly difficult” to determine if liver disease is preexisting, methotrexate related, or caused by other medications or comorbidities, they said. To better assess the issue, they searched PubMed and the Cochrane Central Register of Controlled Trials for relevant double-blind, randomized, controlled trials published between 1990 and 2014. They found 32 such trials that included 13,177 patients with rheumatoid arthritis, psoriasis, psoriatic arthritis or inflammatory bowel disease (Semin Arthritis Rheum. 2015;45:156-62). Methotrexate use approximately doubled the risk of any adverse hepatic event (relative risk, 2.19; 95% confidence interval, 1.73-2.77) and of major and minor liver enzyme abnormalities (RR, 2.16; 95% CI, 1.67-2.79), but did not increase the risk of liver failure, cirrhosis, or liver-related mortality (RR, 0.12; 95% CI, 0.01-1.09), the investigators reported. “Clinical trials have inherent limitations, including short duration, selection bias, failure to collect information or reports that are not part of a prespecified protocol, and limited power to evaluate rare or unusual reports,” they cautioned. “While meta-analyses help overcome the last of these, the others raise some concern.”

But several other reports align with their results, the researchers noted. In an analysis of methotrexate studies lasting at least 2 years, about 10% of patients developed at least one minor liver enzyme abnormality, but less than 4% stopped methotrexate because of liver toxicity. Other controlled studies did not link methotrexate to severe fibrosis or cirrhosis – even after 4 years of treatment, they added. “It appears likely that serious liver-related complications due to methotrexate may take many years of treatment to manifest,” the investigators concluded.

The researchers reported no funding sources or conflicts of interest.

Methotrexate use more than doubled the risk of liver enzyme abnormalities but was not tied to serious hepatic outcomes among patients with rheumatic diseases, according to a meta-analysis of 32 randomized, controlled trials.

“Serious liver events were rare, with a suggestion of a trend towards fewer poor liver outcomes,” wrote Dr. Richard Conway of Galway (Ireland) University Hospitals. “The short duration of the included studies and the lack of liver biopsies are limitations, but the available data provide robust evidence for short-term safety” of methotrexate, wrote Dr. Conway and his associates.

Methotrexate is a first-line RA therapy with efficacy in several other inflammatory diseases, but concerns about toxicity have limited its use, the researchers noted. Clinicians have particularly debated its hepatic effects, in part because it can be “exceedingly difficult” to determine if liver disease is preexisting, methotrexate related, or caused by other medications or comorbidities, they said. To better assess the issue, they searched PubMed and the Cochrane Central Register of Controlled Trials for relevant double-blind, randomized, controlled trials published between 1990 and 2014. They found 32 such trials that included 13,177 patients with rheumatoid arthritis, psoriasis, psoriatic arthritis or inflammatory bowel disease (Semin Arthritis Rheum. 2015;45:156-62). Methotrexate use approximately doubled the risk of any adverse hepatic event (relative risk, 2.19; 95% confidence interval, 1.73-2.77) and of major and minor liver enzyme abnormalities (RR, 2.16; 95% CI, 1.67-2.79), but did not increase the risk of liver failure, cirrhosis, or liver-related mortality (RR, 0.12; 95% CI, 0.01-1.09), the investigators reported. “Clinical trials have inherent limitations, including short duration, selection bias, failure to collect information or reports that are not part of a prespecified protocol, and limited power to evaluate rare or unusual reports,” they cautioned. “While meta-analyses help overcome the last of these, the others raise some concern.”

But several other reports align with their results, the researchers noted. In an analysis of methotrexate studies lasting at least 2 years, about 10% of patients developed at least one minor liver enzyme abnormality, but less than 4% stopped methotrexate because of liver toxicity. Other controlled studies did not link methotrexate to severe fibrosis or cirrhosis – even after 4 years of treatment, they added. “It appears likely that serious liver-related complications due to methotrexate may take many years of treatment to manifest,” the investigators concluded.

The researchers reported no funding sources or conflicts of interest.